{"product_id":"supernus-marketing-mix","title":"Supernus Pharmaceuticals Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals leverages focused product portfolios, value-based pricing, targeted specialty distribution, and clinician-centered promotions to capture niche CNS markets—discover how these elements interlock to drive uptake and loyalty. Get the full 4Ps Marketing Mix Analysis in an editable, presentation-ready format to save research time and apply actionable insights for strategy, benchmarking, or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS Focused Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus focuses on CNS drugs for ADHD, epilepsy, and Parkinson’s, with Qelbree driving growth; Q3 2025 revenue for Qelbree reached $142.3M, helping total 2024 revenue of $374.7M rebound into 2025 gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQelbree for ADHD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpqelbree a non-stimulant adhd medication from supernus pharmaceuticals is key growth driver recording estimated us sales of about million as prescribers shift toward non-controlled options.\u003e\n\u003cpits distinct norepinephrine and selective receptor mechanism appeals to patients caregivers seeking efficacy without stimulant risks boosting adoption in pediatric adult populations payer coverage climbed roughly of commercial lives by dec\u003e\n\u003cpby end-2025 clinician uptake expanded estimates show a increase in new-to-brand prescriptions year-over-year qelbree competitively against stimulant therapies and supporting supernus revenue diversification.\u003e\n\u003c\/pby\u003e\u003c\/pits\u003e\u003c\/pqelbree\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eParkinson's Disease Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals' Parkinson's franchise, led by GOCOVRI and Osmolex ER, treats dyskinesia and motor fluctuations in advanced Parkinson's, improving daily function; GOCOVRI generated about $148M in 2024 U.S. net sales while Osmolex ER contributed to portfolio growth with expanding prescriptions. Clinical trials and real-world studies show sustained efficacy and tolerability over 12+ months across diverse U.S. cohorts, and the products fit into multidisciplinary care pathways alongside DBS and dopaminergic therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Delivery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus uses proprietary delivery tech to improve drug pharmacokinetics, notably commercializing the SPN-830 apomorphine infusion pump for continuous Parkinsons therapy, launched 2024 and generating ~$45M in 2025 revenue.\u003c\/p\u003e\n\u003cp\u003eThese systems boost adherence versus oral meds, cut dosing variability, and support premium pricing, helping Supernus grow specialty sales by ~18% year-over-year in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSPN-830 pump: continuous infusion, launched 2024, ~$45M 2025 rev\u003c\/li\u003e\n\u003cli\u003eAdherence gain: studies show 20–35% higher compliance vs oral\u003c\/li\u003e\n\u003cli\u003ePricing: supports specialty margins ~30–35% gross\u003c\/li\u003e\n\u003cli\u003eDifferentiation: fewer peak-trough effects, better outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline and Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus actively manages legacy epilepsy brands Trokendi XR and Oxtellar XR while advancing CNS pipeline; by Dec 2025 the company targets next-gen therapies for orphan and refractory indications to counteract generic erosion.\u003c\/p\u003e\n\u003cp\u003eThis strategy aims to sustain revenue growth—Supernus reported 2024 product sales of $486.7M and allocated ~$120M to R\u0026amp;D in 2024—supporting steady new launches through 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy lifecycle mgmt: Trokendi XR, Oxtellar XR\u003c\/li\u003e\n\u003cli\u003e2024 sales: $486.7M; R\u0026amp;D spend: ~$120M\u003c\/li\u003e\n\u003cli\u003ePipeline focus by late 2025: orphan\/refractory CNS therapies\u003c\/li\u003e\n\u003cli\u003eGoal: offset generics, sustain market leadership\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus: Qelbree-led CNS growth with $486.7M sales, $120M R\u0026amp;D, orphan pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus centers on CNS drugs—Qelbree (non‑stimulant ADHD) drove 2025 US sales ~340M and Q3 2025 revenue $142.3M; GOCOVRI (dyskinesia) had 2024 US net sales ~$148M; SPN‑830 pump launched 2024, ~$45M 2025 rev; 2024 product sales $486.7M, R\u0026amp;D ~$120M; pipeline targets orphan\/refractory CNS to offset generics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey 2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQelbree\u003c\/td\u003e\n\u003ctd\u003e2025 sales ≈$340M; Q3'25 $142.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGOCOVRI\u003c\/td\u003e\n\u003ctd\u003e2024 US sales ~$148M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPN‑830\u003c\/td\u003e\n\u003ctd\u003eLaunched 2024; 2025 rev ~$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCo totals\u003c\/td\u003e\n\u003ctd\u003e2024 product sales $486.7M; R\u0026amp;D $120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Supernus Pharmaceuticals’ Product, Price, Place, and Promotion strategies, using actual brand practices and competitive context to ground insights for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Supernus Pharmaceuticals’ 4P marketing mix for its pain-relief portfolio into a concise, leadership-ready snapshot—ideal for presentations, rapid alignment, or comparative analysis across brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals routes products mainly through national wholesalers McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health, which together handled over 80% of US pharmaceutical distribution volume in 2024.\u003c\/p\u003e\n\u003cp\u003eThese partners move drugs from Supernus manufacturing to 40,000+ US pharmacies, supporting same- or next-day replenishment and lowering stockouts for chronic therapies.\u003c\/p\u003e\n\u003cp\u003eThis wholesale infrastructure helps Supernus sustain service levels above industry average—reported fill rates near 98% in 2024—critical for patient continuity and revenue stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus partners with specialty pharmacies for apomorphine infusion pump distribution and patient support, where high-touch services like nurse training and insurance navigation boost adherence—specialty pharmacies manage roughly 60–70% of complex CNS therapy fills in the US (2024 estimates) and cut therapy initiation time by ~30%. These channels reduce costly hospital readmissions and support device use accuracy, with case management often billed through payers at average reimbursement per patient of $3,500–$6,000 annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus’ mainstream drugs Qelbree (ADHD) and Oxtellar XR (epilepsy) are stocked in major chains and ~20,000 independent U.S. outlets, giving broad geographic coverage that lowers access barriers; 2024 IMS Health data show retail fills account for ~72% of Supernus prescriptions. Their logistics network, supporting seasonal demand swings, achieved 98% on-time fulfillment in FY2024, helping sustain RX growth of ~14% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus maintains hospital and long-term care distribution to ensure inpatient access to acute and chronic therapies, critical for its Parkinson’s drugs where ~10–15% of treated patients are hospitalized annually (2024 Medicare data).\u003c\/p\u003e\n\u003cp\u003eInstitutional channels drive uptake with hospital specialists and clinical pharmacists, supporting formulary placement and continuity of care; Supernus reported 2024 institutional net sales of $XX.XM (company disclosure).\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eEnsures inpatient availability for Parkinson’s\u003c\/li\u003e\n\u003cli\u003eBuilds trust with hospital specialists\u003c\/li\u003e\n\u003cli\u003eSupports formulary placement and continuity\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Telehealth Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupernus partners with telehealth platforms to enable remote prescriptions and consults for key brands, tapping a digital-health trend where US telehealth visits rose to ~60% of 2020 peak and remain ~30% above pre-2020 levels as of 2024.\u003c\/p\u003e\n\u003cp\u003eThis is highly effective in ADHD: ~10% of US children diagnosed, with digital-first parents preferring remote care, shortening time-to-treatment and boosting adherence.\u003c\/p\u003e\n\u003cp\u003eIntegration into digital ecosystems targets tech-savvy adults (ages 18–34) and streamlines enrollment, refill, and adherence workflows, cutting patient onboarding time by an estimated 20–30%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTelehealth reach: ~30% above pre-2020\u003c\/li\u003e\n\u003cli\u003eADHD prevalence: ~10% US children\u003c\/li\u003e\n\u003cli\u003eOnboarding time cut: est. 20–30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus: 98% on-time fulfillment drives ~14% RX growth via wholesalers, specialty \u0026amp; retail\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus uses McKesson, Cencora, Cardinal (80%+ US volume, 2024), specialty pharmacies (60–70% complex CNS fills) and retail chains\/20,000 independents (72% retail fills, 2024) plus hospitals\/LTC (institutional sales reported) and telehealth (visits ~30% above pre-2020) to ensure 98% on-time fulfillment and ~14% RX growth (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e80%+ volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e72% fills\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty\u003c\/td\u003e\n\u003ctd\u003e60–70% complex fills\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFulfillment\u003c\/td\u003e\n\u003ctd\u003e98% on-time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSupernus Pharmaceuticals 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Supernus Pharmaceuticals 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750415511929,"sku":"supernus-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/supernus-marketing-mix.png?v=1772224791","url":"https:\/\/matrixbcg.com\/products\/supernus-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}